Skip to content

Study · Randomized controlled trial · n = 80 · 2025

8 results

Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial.

Chen H, Lei X, Yang Z, Xu Y, Liu D, Wang C, Du H

Reproductive biology and endocrinology : RB&E26 Jul 2025Cited by 12 (Europe PMC)

PMID40713699 (opens in a new tab)PMCIDPMC12297736 (opens in a new tab)DOI10.1186/s12958-025-01447-3 (opens in a new tab)PepBankPUB-40713699
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding semaglutide to metformin reduced body weight more than metformin alone after 16 weeks (6.09 vs 2.25 kg).

    In plain wordsIn women with PCOS and overweight, semaglutide plus metformin led to more weight loss than metformin alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight reduction at week 16
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Measurements

    weight loss
    6.09 kg
    semaglutide plus metformin
    weight loss
    2.25 kg
    metformin

    Source sentences

    Summary
    After 16 weeks of intervention, the COM group exhibited significantly greater reductions in body weight, BMI, and waist-to-hip ratio (WHR) compared to the MET group (all P < 0.01).
    3 context sentences
    Summary · context
    The COM group experienced an average weight loss of 6.09 ± 3.34 kg, while the MET group lost only 2.25 ± 4.27 kg.
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding semaglutide to metformin reduced BMI more than metformin alone after 16 weeks.

    In plain wordsIn women with PCOS and overweight, semaglutide plus metformin lowered body mass index more than metformin alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseBMI reduction at week 16
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    After 16 weeks of intervention, the COM group exhibited significantly greater reductions in body weight, BMI, and waist-to-hip ratio (WHR) compared to the MET group (all P < 0.01).
    2 context sentences
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding semaglutide to metformin reduced waist-to-hip ratio more than metformin alone after 16 weeks.

    In plain wordsIn women with PCOS and overweight, semaglutide plus metformin lowered waist-to-hip ratio more than metformin alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist-to-hip ratio reduction at week 16
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    After 16 weeks of intervention, the COM group exhibited significantly greater reductions in body weight, BMI, and waist-to-hip ratio (WHR) compared to the MET group (all P < 0.01).
    2 context sentences
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding semaglutide to metformin gave greater improvement in testosterone than metformin alone.

    In plain wordsIn women with PCOS and overweight, semaglutide plus metformin improved testosterone levels more than metformin alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedTestosterone
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Analysis
    Secondary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The COM group also demonstrated greater improvements in testosterone (TEST)
    3 context sentences
    Summary · context
    compared to the MET group.
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding semaglutide to metformin gave greater improvement in CRP than metformin alone.

    In plain wordsIn women with PCOS and overweight, semaglutide plus metformin improved an inflammation marker more than metformin alone.

    Peptide
    Semaglutide
    Outcome
    DecreaseC-reactive protein
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Analysis
    Secondary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The COM group also demonstrated greater improvements in testosterone (TEST), Chinese visceral adiposity index (CVAI), and CRP levels compared to the MET group.
    3 context sentences
    Summary · context
    decreased inflammatory markers
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, adding semaglutide to metformin gave greater improvement in the Chinese visceral adiposity index than metformin alone.

    In plain wordsIn women with PCOS and overweight, semaglutide plus metformin improved a measure of belly fat more than metformin alone.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedChinese visceral adiposity index
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The COM group also demonstrated greater improvements in testosterone (TEST), Chinese visceral adiposity index (CVAI), and CRP levels compared to the MET group.
    2 context sentences
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, the semaglutide plus metformin group showed higher rates of menstrual cycle recovery than the metformin group.

    In plain wordsIn women with PCOS and overweight, more women recovered regular periods with semaglutide plus metformin than with metformin alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseMenstrual cycle recovery
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Additionally, the COM group showed higher rates of menstrual cycle recovery than the MET group.
    2 context sentences
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In overweight or obese women with PCOS, the natural pregnancy rate from weeks 16 to 40 was higher after semaglutide plus metformin than after metformin (35% vs. 15%).

    In plain wordsIn women with PCOS and overweight, natural pregnancy was more common after semaglutide plus metformin than after metformin alone.

    Peptide
    Semaglutide
    Outcome
    IncreaseNatural pregnancy rate weeks 16 to 40
    Study

    n = 80

    Comparator
    Metformin monotherapy
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    1 mg once weekly · 16 weeksAs given in this study (human).

    Measurements

    natural pregnancy rate
    35%
    semaglutide plus metformin
    natural pregnancy rate
    15%
    metformin

    Source sentences

    Summary
    From weeks 16 to 40, the COM group demonstrated a significantly higher natural pregnancy rate than the MET group (35% vs. 15%, P < 0.05).
    2 context sentences
    Summary · context
    A total of 100 overweight or obese women with PCOS diagnosed according to the Rotterdam criteria were randomly assigned to two groups: MET (1000 mg twice daily [BID] for 16 weeks) and combination therapy (COM) (1000  mg MET BID plus 1- mg semaglutide once weekly [QW] for 16 weeks).
    Summary · context
    A total of 80 participants (80%) completed the study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.